Free, personalized support for people taking GOMEKLI (mirdametinib)
Actor portrayal.
SpringWorks CareConnections is a free, personalized patient support program to help you navigate your insurance coverage and answer questions about your treatment
If you have been prescribed GOMEKLI, ask your healthcare provider to help you enroll in the SpringWorks CareConnections Patient Support Program or click on the button below to get started.
Insurance navigation and financial help
Our team of Nurse Advocates can provide information about financial assistance options, as well as explain your insurance coverage for GOMEKLI.
Commercially insured patients may pay as little as a $0 copay per 21-day supply of GOMEKLI with the Commercial Copay Program.*
The program may also help with eligible out-of-pocket costs for certain treatment-related tests, examinations, and/or specialty visits during treatment with GOMEKLI.
Support may be available through SpringWorks CareConnections to help you save on GOMEKLI.
(844-227-3755)
Monday – Friday, 8AM – 10PM ET
for more information
*Terms and conditions apply. Copay program for GOMEKLI and reimbursement for eligible treatment-related costs are subject to annual benefit maximums. To receive the reimbursement of eligible treatment-related expenses, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. Full terms and conditions are provided during the enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).
Independent Patient Assistance Foundations
Financial assistance may be available through independent foundations that are not controlled by or otherwise affiliated with SpringWorks Therapeutics. These foundations may be able to assist with copays, premiums, patient education, social services, etc.
SpringWorks Therapeutics does not influence or control the operations of independent patient assistance foundations and cannot guarantee assistance will be provided. Details and eligibility requirements can be found directly on the individual foundation websites.
Explore additional foundations that may be able to help with financial assistance
Personalized educational and emotional support for patients
Our team of Nurse Advocates† can provide treatment support as it relates to your condition, as well as ongoing, personalized support no matter where you are in your treatment journey with GOMEKLI.
Whether you are taking GOMEKLI or are living with or caring for a loved one taking GOMEKLI, SpringWorks CareConnections can provide support and encouragement to help you or your loved one stay on track and take the medication as prescribed.
†The SpringWorks CareConnections Patient Support Program is not intended to take the place of your healthcare provider, and our team of Nurse Advocates cannot provide medical or clinical advice.
Helpful Resources
Living with or caring for someone with NF1-PN can be challenging. Our resources can help you throughout your journey with GOMEKLI.
NF1-PN=neurofibromatosis type 1 with plexiform neurofibromas.
What is GOMEKLI?
GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.
It is not known if GOMEKLI is safe and effective in children under 2 years of age.
Important Safety Information
Before taking GOMEKLI, tell your healthcare provider about all of your medical conditions, including if you:
- Have eye problems
- Have heart problems
- Are pregnant or plan to become pregnant. GOMEKLI can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider should check to see if you are pregnant before you begin treatment with GOMEKLI.
- Use effective birth control (contraception) during treatment with GOMEKLI and for 6 weeks after your last dose.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with GOMEKLI.
Males with female partners who are able to become pregnant:
- Use effective birth control (contraception) during treatment with GOMEKLI and for 3 months after your last dose.
- Tell your healthcare provider right away if your female partner becomes pregnant or thinks she may be pregnant during treatment with GOMEKLI.
- Are breastfeeding or plan to breastfeed. It is not known if GOMEKLI passes into your breast milk.
- Do not breastfeed during treatment with GOMEKLI and for 1 week after your last dose.
- Talk to your healthcare provider about the best way to feed your baby during this time.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I take GOMEKLI?
- Take GOMEKLI exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GOMEKLI if you develop certain side effects.
- Take GOMEKLI twice a day, about 12 hours apart, for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Your healthcare provider will decide how many treatment cycles are right for you.
- Take GOMEKLI with or without food.
- GOMEKLI comes in two different dosage forms, GOMEKLI capsules and GOMEKLI tablets for oral suspension. Your healthcare provider will decide the dosage form and dose of GOMEKLI that is right for you.
- If you take GOMEKLI capsules: Swallow each capsule whole with drinking water. If more than 1 capsule is required, swallow 1 capsule at a time. Do not open, break or chew the capsules.
- If you take GOMEKLI tablets for oral suspension, either:
- Swallow each tablet for oral suspension whole with drinking water. If more than 1 tablet is required, swallow 1 tablet at a time.
- Disperse the tablets for oral suspension in drinking water to make a liquid (suspension) before you take or give GOMEKLI.
OR
See the “Instructions for Use” that come with your medicine for instructions on how to prepare and take GOMEKLI tablets for oral suspension.
- If you miss a dose of GOMEKLI, skip the missed dose and take your next dose at your regularly scheduled time.
- If you vomit at any time after taking GOMEKLI, do not take an additional dose. Take your next dose at your regularly scheduled time.
What are the possible side effects of GOMEKLI?
- Eye problems. GOMEKLI may cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with GOMEKLI. Tell your healthcare provider right away if you get any of the following signs or symptoms of eye problems:
- Blurred vision
- Loss of vision
- Other changes to your vision
- Heart problems. GOMEKLI may lower the amount of blood pumped by your heart, which is common in children during treatment with GOMEKLI and can also be severe. Your healthcare provider will do tests before you start GOMEKLI treatment, every 3 months during your first year of treatment, and then as needed to make sure your heart is working properly. Tell your healthcare provider right away if you get any of the following signs or symptoms of heart problems:
- Coughing or wheezing
- Shortness of breath
- Swelling of your ankles and feet
- Tiredness
- Increased heart rate
- Skin problems. Skin rashes are common with GOMEKLI in both adults and children and can also be severe. GOMEKLI can also cause hair loss (alopecia). Tell your healthcare provider if you develop any of the following signs or symptoms of skin problems:
- Flat skin rash
- Raised bumps on the skin
- Skin bumps that look like acne
- Skin redness
- Itchy rash
- Peeling skin
The most common side effects of GOMEKLI in adults include:
- Diarrhea
- Nausea
- Muscle, joint, and bone pain
- Vomiting
- Tiredness
The most common side effects of GOMEKLI in children include:
- Diarrhea
- Muscle, joint, and bone pain
- Stomach (abdominal) pain
- Vomiting
- Headache
- Skin redness, swelling, or pain around the fingernails or toenails
- Nausea
What is GOMEKLI?
It is not known if GOMEKLI is safe and effective in children under 2 years of age.